Could an Olive-Oil Spread Lower LDL Cholesterol in Children Before Medication Is Needed?

Study Overview

The paper, “Chemometrics-guided plasma lipidomics insights underlying the decrease of plasma total cholesterol and LDLc in children with hypercholesterolemia following habitual intake of an EVOO-based phytosterols-enriched spreadable cream,” was published in Metabolomics in 2025 by García-Pérez, Vázquez-Aguilar, Sánchez-Rodríguez and colleagues. It was a randomized, double-blind, crossover controlled clinical study registered as NCT05460208.

The intervention was a spreadable cream using a 90% extra-virgin olive-oil base. The active version added 1.2 g of free phytosterols per 15 g dose, while the control used the same EVOO spread without added sterols. Children weighing more than 20 kg and less than 40 kg received one 15 g dose per day; children from 40 to 60 kg received two doses. That translated to roughly 0.03–0.06 g plant sterols per kg body weight per day.

Fifty children aged 6–18 years were included after screening; 24 started with control and 26 started with the phytosterol-enriched EVOO spread. Each treatment period lasted 8 weeks, separated by a 4-week washout, then participants crossed over. The final high-compliance analysis was much smaller: 23 children met the study's ≥70% adherence threshold, with 10 in sequence A and 13 in sequence B.

Key Findings: The Actual Numbers

Baseline LDL-C was genuinely high for children: the two sequence groups both averaged 141 mg/dL LDL-C at baseline. Total cholesterol averaged 224 ± 8 mg/dL in group A and 213 ± 11 mg/dL in group B. The study also reports that 74% of the adherent children were normal-weight, 12% overweight, and 14% obese, so this was not merely a weight-loss story disguised as a cholesterol intervention.

Mechanism: Why This Might Work

The cleanest mechanism is not mystical olive-oil antioxidant magic. It is plant-sterol biology. Phytosterols resemble cholesterol structurally, so they compete with cholesterol during intestinal micelle formation, reduce cholesterol absorption, and increase fecal sterol loss. The EVOO base matters because it makes the intervention a Mediterranean-style food matrix rather than a pill, but the added sterols are likely the primary LDL-lowering driver.

The lipidomics layer adds a useful biological clue. The researchers annotated 1,948 plasma lipid features. In the multiblock OPLS model, “Group × Treatment” explained 14.8% of model variability with p = 0.01, while “Time × Treatment” was also significant at p = 0.04. The most discriminating lipid classes were phospholipids/lysophospholipids and sphingolipids, each representing about 20% of the key VIP markers. In plain English: the blood lipid profile shifted in ways consistent with altered lipoprotein assembly, transport, and membrane-related lipid metabolism.

Several individual lipid signals moved in the expected direction. For example, PE P-15:2/17:4 was higher after the phytosterol-enriched spread at t2 versus control (logFC 1.58; p < 0.05), DAG 33:6 was also higher (logFC 1.26; p < 0.05), and one vitamin A fatty-acid ester signal, VAE 6:0, increased (logFC 0.41; p < 0.05). These are exploratory markers, not clinical endpoints, but they make the LDL-C result feel more biologically coherent.

Context: How It Fits the Wider Evidence

Adult evidence already suggests plant sterols can lower LDL-C, often around 10–15% at daily intakes near 2–3 g. This pediatric trial lands in that same zone, with a 17.2% LDL-C reduction in the adherent analysis. That is clinically meaningful if it holds up, because childhood LDL-C tracks into adult cardiovascular risk and early arterial changes can begin long before symptoms appear.

But this study should not be confused with a trial of plain extra virgin olive oil. The control was also EVOO-based. The active difference was the phytosterol enrichment. For our evidence map, that makes the paper important in a specific lane: EVOO as a functional-food platform for lipid lowering, not EVOO alone as a pediatric cholesterol drug.

Practical Takeaway

For adults reading this, the practical lesson is straightforward: if LDL-C is the target, the strongest food-based evidence points toward replacing saturated fat with unsaturated fats, increasing soluble fiber, and, when appropriate, using plant-sterol-enriched foods. High-quality EVOO still belongs in that pattern, especially as the fat that replaces butter or refined seed-oil-heavy ultra-processed foods.

For children, this is clinician territory. A child with persistent LDL-C around 140 mg/dL deserves proper assessment, family-history review, and medical follow-up. A phytosterol-enriched EVOO food may become a useful dietary tool, but it should not delay diagnosis of familial hypercholesterolemia or replace professional care.

Limitations

• Small usable sample: 50 children entered, but only 23 met the ≥70% compliance threshold used for final analyses.
• Baseline imbalance: HDLc and alkaline phosphatase differed between sequence groups at baseline, and the authors note biomarker bias between groups.
• Functional food, not plain EVOO: because both spreads used EVOO, the LDL-C effect belongs mainly to phytosterol enrichment.
• Short duration: each treatment lasted 8 weeks, so we do not know long-term adherence, durability, growth effects, or cardiovascular outcomes.
• Industry involvement in product manufacture: Acer Campestres made the spreads, although the authors state the company was not involved in design, data collection, analysis, interpretation, writing, or submission.

Our Take

This is not game-changing on its own, but it is much better than a typical “olive oil is healthy” paper. The design is serious: randomized, double-blind, crossover, registered, with a control that isolates the added phytosterols reasonably well. The LDL-C signal is also large enough to care about: 17.2% lower LDL-C is not cosmetic.

The weakness is power. Twenty-three adherent children is too small for sweeping pediatric guidance, and the compliance drop-off is itself a real-world warning. Still, the study gives a credible direction: the future of olive-oil health products may not be “drink more oil.” It may be smarter food matrices that use EVOO as the base, then add evidence-backed bioactives such as phytosterols where the mechanism is already strong.